Iovance Biotherapeutics Stock (NASDAQ: IOVA)

Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

benzingaai2023_modern_computer_screen_with_stock_chart_stock__c8dae12f-563b-4c3d-ba96-79a17f4c62e4_0

News

Movers

IOVA

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares closed lower on Monday potentially following the company&#39;s announcement of Dan Kirby as Chief Commercial Officer.

Iovance Biotherapeutics Shares Fell Today: What&#39;s Going On?

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) are trading lower Friday. The company announced the inducement stock option grants under Nasdaq Listing Rule 5635(c)(4). 

Iovance Biotherapeutics Shares Are Falling Today: What&#39;s Going On?

Nvidia, Palantir, Clover Health, Joby Aviation, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Intraday Update

Markets

ACHR

BBIO

BBWI

CLVT

ESTC

EVEX

FIVE

Hims & Hers Health, Inc. Class A Common Stock

HIMS

KODK

MRNA

QBTS

QUBT

RGTI

SMCI

SRRK

BridgeBio Pharma, Rigetti Computing, Bath &amp; Body Works And Other Big Stocks Moving Higher On Monday

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics Inc

Earnings

Press Releases

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

Small Cap

Opinion

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

Management

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024

IBRX

ONCY

SNDX

SWTX

TSX:ONC

Truist Securities

Goldman Sachs

Chardan Capital

Baird

Piper Sandler

Screenshot 2024-05-28 at 5.34.55 PM

Biotech

General

CPMV

OTLC

Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets

Comments

Iovance Biotherapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga